Nebenwirkungen · Amgevita
AMGEVITA 20 mg solution for injection in pre-filled syringe AMGEVITA 40 mg solution for injection in pre-filled syringe AMGEVITA 40 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 21
HOS-224896 · Präparat HOS-217372
In controlled and open-label adult and paediatric studies with adalimumab, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after initiation of therapy and may reflect recrudescence of latent disease.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T02:00:00Z · SHA-256 e60d722f3b6745489b45f5c78ae97b6371cdaa2129d753a34a831ca4ba40a8b5 · Passage 9b978fbb40af5e052653641cbda2f99094288a5a7e3b5cbfc5e5a9acc20182e5 · Zeichen 15516–16104 im Abschnitt